Celcuity, Inc. (NASDAQ:CELC - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $55.93, but opened at $58.94. Celcuity shares last traded at $58.06, with a volume of 43,289 shares trading hands.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on the stock. HC Wainwright boosted their price objective on shares of Celcuity from $50.00 to $66.00 and gave the company a "buy" rating in a research note on Monday, August 18th. Stifel Nicolaus assumed coverage on shares of Celcuity in a research note on Tuesday, July 1st. They set a "buy" rating and a $30.00 price objective for the company. Needham & Company LLC lowered their price objective on shares of Celcuity from $74.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, August 15th. Finally, Leerink Partners boosted their price objective on shares of Celcuity from $28.00 to $60.00 and gave the company an "outperform" rating in a research note on Monday, July 28th. Four research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $56.50.
Check Out Our Latest Research Report on CELC
Celcuity Price Performance
The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58. The firm has a market cap of $2.25 billion, a price-to-earnings ratio of -15.38 and a beta of 0.72. The company's fifty day moving average is $39.65 and its two-hundred day moving average is $20.90.
Celcuity (NASDAQ:CELC - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.14). Equities research analysts forecast that Celcuity, Inc. will post -2.62 EPS for the current year.
Insider Buying and Selling
In other Celcuity news, Director David Dalvey sold 100,000 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $43.98, for a total value of $4,398,000.00. Following the transaction, the director owned 125,000 shares in the company, valued at $5,497,500. The trade was a 44.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 15.78% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Celcuity
Institutional investors have recently modified their holdings of the stock. Trexquant Investment LP raised its stake in shares of Celcuity by 131.3% in the 1st quarter. Trexquant Investment LP now owns 26,920 shares of the company's stock valued at $272,000 after purchasing an additional 15,280 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Celcuity by 45.9% in the 4th quarter. Ameriprise Financial Inc. now owns 447,171 shares of the company's stock valued at $5,853,000 after purchasing an additional 140,642 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Celcuity by 16.2% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,725 shares of the company's stock valued at $258,000 after purchasing an additional 2,756 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Celcuity by 3.9% in the 4th quarter. Bank of America Corp DE now owns 288,259 shares of the company's stock valued at $3,773,000 after purchasing an additional 10,907 shares in the last quarter. Finally, Baker BROS. Advisors LP raised its stake in shares of Celcuity by 59.0% in the 1st quarter. Baker BROS. Advisors LP now owns 4,257,735 shares of the company's stock valued at $43,046,000 after purchasing an additional 1,579,182 shares in the last quarter. Institutional investors and hedge funds own 63.33% of the company's stock.
Celcuity Company Profile
(
Get Free Report)
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Recommended Stories
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
